NASDAQ
07.08.26 | 21:59
17,685 US-Dollar
-0,25 % -0,045
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | 399 | GlobeNewswire (Europe) | CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase... ► Artikel lesen | |
| Do | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| Do | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 28.07. | Cullinan Therapeutics: Positive FDA-Rückmeldung treibt Aktie an | 3 | Investing.com Deutsch | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.07. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML | 226 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; "Cullinan"), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class... ► Artikel lesen | |
| 16.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.06. | William Blair reiterates Cullinan Oncology stock rating on trial data | 3 | Investing.com | ||
| 10.06. | William Blair bestätigt "Outperform"-Rating für Cullinan Oncology nach Studiendaten | 1 | Investing.com Deutsch | ||
| 10.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases | 10 | GlobeNewswire (USA) | ||
| 08.06. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 06.06. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress | 3 | GlobeNewswire (USA) | ||
| 28.05. | Morocco and Finland Launch Business Council in Helsinki as Tazi Makes First European Outing as CGEM President | 2 | North Africa Post | ||
| 19.05. | Stifel reiterates Cullinan Oncology stock rating on trial data | 6 | Investing.com | ||
| 19.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 301 | GlobeNewswire (Europe) | Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan... ► Artikel lesen | |
| 18.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 15.05. | Tazi and Bachiri Elected to Lead CGEM with 91.5% of the Vote | 1 | North Africa Post | ||
| 07.05. | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | 2 | North Africa Post | ||
| 07.05. | Cullinan Therapeutics GAAP EPS of -$0.75 | 2 | Seeking Alpha | ||
| 07.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,666 | -1,05 % | Clinuvel Pharmaceuticals Limited: CLINUVEL implements strategic reorganisation to refocus on U.S. markets | MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce... ► Artikel lesen | |
| EDITAS MEDICINE | 2,550 | +2,41 % | Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2026 Results and Business Updates | EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins,... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,236 | +0,98 % | Stocks in Play: Cardiol Therapeutics Inc. | ||
| CELLECTAR BIOSCIENCES | 2,560 | -0,39 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,168 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,833 | -3,48 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 4,340 | +3,88 % | Emergent BioSolutions Reports Second Quarter 2026 Financial Results | Second Quarter 2026 Total Revenues of $234.3 million, an improvement of 66% versus prior yearSecond Quarter 2026 Net Loss of $180.2 million worsening 1,402% versus prior year, largely due to a $191.3... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,000 | +2,52 % | DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum | ||
| CEL-SCI | 1,500 | +2,74 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| CYTOKINETICS | 66,28 | -0,12 % | Cytokinetics, Incorporated: Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update | MYQORZO- (aficamten) Net Product Revenue of $25 Million Full Results from ACACIA-HCM to be Presented in Hot Line Session at ESC; Expect to Submit Supplemental NDA for Aficamten in Non-Obstructive... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,098 | +0,27 % | Coherus Oncology, Inc.: Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update | - LOQTORZI net revenue of $13.6 million in Q2 2026, up 15% over Q1 - - Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer -... ► Artikel lesen | |
| CURIS | 3,405 | 0,00 % | Curis, Inc.: Curis Doses First Five Patients in TakeAim CLL Study | LEXINGTON, Mass., July 30, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,929 | +0,83 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors | SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,294 | -5,13 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) | ||
| FAETH THERAPEUTICS | 24,390 | 0,00 % | Sensei BioTherapeutics GAAP EPS of -$2.84 |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,045 (-0,25 %) liegt der Kurs bei 17,685 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.